Headlands Technologies LLC Sells 3,915 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Headlands Technologies LLC lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 67.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,922 shares of the company's stock after selling 3,915 shares during the period. Headlands Technologies LLC's holdings in Neurocrine Biosciences were worth $213,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of NBIX. LPL Financial LLC raised its position in shares of Neurocrine Biosciences by 27.8% during the fourth quarter. LPL Financial LLC now owns 16,754 shares of the company's stock worth $2,287,000 after purchasing an additional 3,643 shares during the period. Cerity Partners LLC raised its position in Neurocrine Biosciences by 7.0% in the 4th quarter. Cerity Partners LLC now owns 41,737 shares of the company's stock valued at $5,290,000 after buying an additional 2,713 shares during the last quarter. Invesco Ltd. raised its position in Neurocrine Biosciences by 8.6% in the 4th quarter. Invesco Ltd. now owns 949,512 shares of the company's stock valued at $129,608,000 after buying an additional 74,847 shares during the last quarter. FIL Ltd raised its position in Neurocrine Biosciences by 20.5% in the 4th quarter. FIL Ltd now owns 14,417 shares of the company's stock valued at $1,968,000 after buying an additional 2,452 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its position in Neurocrine Biosciences by 16.4% in the 4th quarter. Kennedy Capital Management LLC now owns 36,112 shares of the company's stock valued at $4,929,000 after buying an additional 5,093 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Stock Up 2.1%

Shares of NBIX traded up $2.73 during mid-day trading on Wednesday, hitting $131.62. 1,056,635 shares of the company's stock were exchanged, compared to its average volume of 1,286,120. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $154.87. The stock's 50-day simple moving average is $128.93 and its 200-day simple moving average is $120.07. The firm has a market cap of $13.05 billion, a price-to-earnings ratio of 38.94, a price-to-earnings-growth ratio of 0.89 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million during the quarter, compared to analysts' expectations of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The company's quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.63 EPS. Analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares of the company's stock, valued at $638,550. The trade was a 8.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the transaction, the insider directly owned 18,289 shares of the company's stock, valued at $2,385,982.94. This represents a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 196,573 shares of company stock valued at $25,112,766 in the last three months. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NBIX. JPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $140.00 to $145.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Royal Bank Of Canada lowered their price target on Neurocrine Biosciences from $146.00 to $144.00 and set an "outperform" rating on the stock in a research report on Thursday, July 31st. Piper Sandler boosted their price target on Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Truist Financial began coverage on Neurocrine Biosciences in a research report on Monday, July 21st. They set a "buy" rating and a $163.00 price target on the stock. Finally, HC Wainwright lowered their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $160.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.